|

SNDX-5613 Clinical Trials

2 actively recruiting trials across 2 locations

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • Syndax Pharmaceuticals1
  • M.D. Anderson Cancer Center1

Indications

  • Cancer2
  • Acute Myeloid Leukemias1
  • Acute Myeloid Leukemia1

Burbank, California1 trial

A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

UCLA Medical Hematology

Phase 1

Houston, Texas1 trial

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

M D Anderson Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.